A US pharmaceutical company has shown that two cannabinoids, cannabichromene (CBC) and cannabigerol (CBG), positively affect gastrointestinal cancer cells. A gastrointestinal stromal tumor (GIST) is a malignant tumor of the gastrointestinal tract.
The tumor originates in the connective tissue of the digestive organs. CBC and CBG showed significant difference from other cannabinoids when it comes to destroying tumor tissue (necrosis).
The company Cannabis Pharmaceuticals Inc. conducted a series of tests in Israel and recently released preliminary results in Maryland. CTO and co-founder Dr. Eyal Ballan affirm the company's vision to personalize cannabinoid treatments. Dr. Ballan says gastrointestinal cancer is one of the most common causes of cancer-related deaths worldwide.
The Cannabics company announced earlier this month that it had signed a memorandum of understanding with RCK medical Cannabis in Israel. This to develop a cannabis chemotype aimed at the treatment of gastrointestinal cancer. RCKMC is a pioneer in the field of plant genetics and has a lot of expertise in this field. Together with the clinical possibilities of Cannabics, this is a hopeful collaboration and a good step in drug development against stomach and colon cancer.
Read more candidchronicle.com (Source, EN)